Tralokinumab
- Generic Name
- Tralokinumab
- Brand Names
- Adbry, Adtralza
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1044515-88-9
- Unique Ingredient Identifier
- GK1LYB375A
- Background
Atopic dermatitis (AD) is an inflammatory skin disorder that causes skin inflammation, skin barrier dysfunction, and chronic pruritus. It is estimated to affect up to 20% of adults and children worldwide, and is frequently associated with other atopic conditions such as asthma or allergic rhinitis. While AD is a heterogenous condition with a variety of apparent genetic and environmental causes, it is primarily driven by the pro-inflammatory cytokine interleukin-13 (IL-13).
Tralokinumab is a fully human IgG4 monoclonal antibody targeted against IL-13. It neutralizes IL-13 activity by inhibiting its ability to bind with receptors, thus helping to alleviate AD symptoms. Tralokinumab was first approved for the treatment of atopic dermatitis by the EMA in June 2021, under the brand name Adtralza (Leo Pharma), and was subsequently approved in Canada in October 2021 and the US in December 2021.
- Indication
Tralokinumab is indicated in Canada, the US, and the EU for the treatment of moderate-to-severe atopic dermatitis in patients who are candidates for systemic therapy and are inadequately controlled with topical interventions. In Canada and US, tralokinumab is only approved for adults. In Europe, it is approved for use in patients 12 years of age and older.
- Associated Conditions
- Moderate to Severe Atopic Dermatitis
- Associated Therapies
- -
The Highly Anticipated FDA Approvals of Galderma's Nemolizumab and Eli Lilly's
The Highly Anticipated FDA Approvals of Galderma's Nemolizumab and Eli Lilly's Lebrikizumab
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.